RGNX - 3 Beaten-Up Biotechs -- Are They Buys?
Biotech stocks have been underperforming, but the drops in Puma Biotechnology (NASDAQ: PBYI), Clovis Oncology (NASDAQ: CLVS), and Regenxbio (NASDAQ: RGNX) have been downright jaw-dropping. Post-approval sales have been slow to materialize for Puma Biotech and Clovis Oncology, respectively, and concerns about regulatory disclosures by a licensee have weighed down Regenxbio. Is it finally time to step up and buy these stocks?
In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Shannon Jones is joined by contributor Todd Campbell to explain what's gone wrong at these companies and, importantly, what could go right from here.
To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, check out our quick-start guide to investing in stocks. A full transcript follows the video.